PIPELINE

PIPELINE OVERVIEW

Biosceptre’s data has shown that drugs directed to nfP2X7 have the potential to treat many common as well as rare cancers whilst avoiding the toxicity seen with many marketed cancer drugs, and we are exploiting this unique profile to build a pipeline of therapeutic and diagnostic products.

Our current efforts are focussed on our exciting new CAR-T constructs with the potential to treat a range of haematologic and solid tumour malignancies.

nfP2X7 CAR-T Program – Direct CAR-T for Haematological Malignancies
OPTIMISATION
nfP2X7 CAR-T ProgramNew CAR-T (details withheld) for Solid Tumours
OPTIMISATION
nfP2X7 Monoclonal Antibody Program – for Haematological & Solid Tumours
OPTIMISATION

SECONDARY PRODUCTS

Available for Out-licensing

  • BIL06v Peptide Vaccine (Phase 1 trial final report due Q3 2020)
  • BIL010t Polyclonal Antibody Topical Therapeutic (BCC)
LICENSING ENQUIRY